Antibody-mediated neutralization is widely accepted to be a major mechanism by which SIV and HIV-1 infection can be aborted. However, the mechanism(s) of this neutralization process in vivo is unknown, and current in vitro assays are insensitive indicators of in vivo virus neutralization. To address this problem, our lab has begun to develop more sensitive neutralization assays to help dissect the early events of virus infection involved in antibody-mediated neutralization (Le., virus binding to the host cell, virus-host cell fusion and virus internalization). For these assays, we will use a unique panel of rhesus monoclonal antibodies derived from monkeys infected with SIV that are divided equally between those that neutralize efficiently and those that fail to demonstrate neutralization in vitro. Our first goal is to define the mechanism of neutralization mediated by these antibodies so that we may identify selected mechanisms to determine the correlation between in vitro neutralization assays and in vivo virus neutralization. Second, we will determine the effects of sequence variation on specific mechanisms of antibody-mediated neutralization. For these studies we will follow the evolution of viral variants that emerge in vivo with the goal of identifying specific changes in the viral envelope that are associated with the transition from a neutralization sensitive to a neutralization insensitive phenotype in vivo. In addition, we will utilize viruses with defined modifications in the envelope (i.e., selected point mutations defined by sequence analyses of viral variants that emerge in vivo, deletions of N-linked glycosylation sites, mutations or deletions within defined variable and/or conserved regions) to correlate mechanisms of virus neutralization with envelope variation. In this manner, we will provide evidence for the specificity and mechanism of antibody-mediated neutralization in vitro, and identify specific genotypic changes that are associated with functional changes in virus neutralization in vivo. These studies will provide a framework to define the role of type-specific and broadly neutralizing antibody in controlling virus infection and disease in the SIV/rhesus macaque model in vivo, a future goal of this laboratory.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI052058-03
Application #
6747342
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Miller, Nancy R
Project Start
2002-06-01
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
3
Fiscal Year
2004
Total Cost
$297,084
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kuhrt, David; Faith, Seth; Hattemer, Angela et al. (2011) Naïve and memory B cells in the rhesus macaque can be differentiated by surface expression of CD27 and have differential responses to CD40 ligation. J Immunol Methods 363:166-76
Milush, Jeffrey M; Mir, Kiran D; Sundaravaradan, Vasudha et al. (2011) Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells. J Clin Invest 121:1102-10
Kuhrt, David; Faith, Seth A; Leone, Amanda et al. (2010) Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J Virol 84:2466-76
Faith, Seth A; Wu, Yingyun; Kuhrt, David et al. (2010) Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation. Virology 400:86-92
Dubie, Robert A; Maksaereekul, Saipiroon; Shacklett, Barbara L et al. (2009) Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-21
Forthal, Donald N; Landucci, Gary; Cole, Kelly Stefano et al. (2006) Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 80:9217-25
Steckbeck, J D; Grieser, H J; Sturgeon, T et al. (2006) Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol 35:248-60
Steckbeck, Jonathan D; Orlov, Irina; Chow, Andrew et al. (2005) Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J Virol 79:12311-20